Protagenic Therapeutics, Inc.\new Payments to Acquire Available-for-sale Securities
Protagenic Therapeutics, Inc.\new (PTIX) reported Payments to Acquire Available-for-sale Securities of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-25.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2021-03-25
- Protagenic Therapeutics, Inc.\new payments to acquire available-for-sale securities for the quarter ending 2018-12-31 was $374.50K, a 35.84% decline year-over-year.
- Protagenic Therapeutics, Inc.\new payments to acquire available-for-sale securities for the quarter ending 2018-09-30 was $592.48K, a 98.45% increase year-over-year.
- Protagenic Therapeutics, Inc.\new payments to acquire available-for-sale securities for the quarter ending 2018-06-30 was $347.69K.
- Protagenic Therapeutics, Inc.\new payments to acquire available-for-sale securities for the quarter ending 2018-03-31 was $1.43M.
- Protagenic Therapeutics, Inc.\new payments to acquire available-for-sale securities for fiscal 2020 was $0.00.
- Protagenic Therapeutics, Inc.\new payments to acquire available-for-sale securities for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- Protagenic Therapeutics, Inc.\new payments to acquire available-for-sale securities for fiscal 2018 was $2.74M, a 20.02% decline from fiscal 2017.
- Protagenic Therapeutics, Inc.\new payments to acquire available-for-sale securities for fiscal 2017 was $3.43M.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-25 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-25 | |||
| 2018-12-31 | $374.50K derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-29 | $966.98K derived: sum of 2 quarters · filed 2020-04-29 | $1.31M derived: sum of 3 quarters · filed 2020-04-29 | $2.74M 10-K · filed 2020-04-29 |
| 2018-09-30 | $592.48K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $940.17K derived: sum of 2 quarters · filed 2019-11-14 | $2.37M 10-Q · filed 2019-11-14 | $2.95M derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | $347.69K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $1.78M 10-Q · filed 2019-08-14 | $2.36M derived: sum of 3 quarters · filed 2019-08-14 | $2.66M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | $1.43M 10-Q · filed 2019-05-16 | $2.01M derived: sum of 2 quarters · filed 2019-05-16 | $2.31M derived: sum of 3 quarters · filed 2019-05-16 | |
| 2017-12-31 | $583.68K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $882.24K derived: sum of 2 quarters · filed 2019-03-29 | $3.43M 10-K · filed 2019-03-29 | |
| 2017-09-30 | $298.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $2.85M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | $2.55M 10-Q · filed 2018-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |